D-0421-2026 Class II Ongoing

Recalled by Appco Pharma LLC — Piscataway, NJ

FDA drug recall D-0421-2026 was initiated by Appco Pharma LLC on Mar 27, 2026 and is designated Class II. Reason for recall: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. The recall status is ongoing. Affected quantity: 28,157 bottles- 100's count.

Recall details

Product Type
Drugs
Report Date
Apr 8, 2026
Initiation Date
Mar 27, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
28,157 bottles- 100's count

Product description

Prazosin Hydrochloride Capsules, USP, 5mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-068-11.

Reason for recall

cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.

Distribution pattern

U.S.A. Nationwide

Code information

Lot:2406255UC, Exp.: 2026/MAY; 2406256UC, Exp.: 2026/JUL; 2407313UC Exp.: 2026/JUL; 2408351UC, Exp.: 2026/JUL; 2408352UC , Exp.: 2026/JUL; 2509311UC, Exp.: 2027/SEP. .

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0421-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0421-2026. Report a data issue: hello@regdatalab.com.